DECISION OF THE EUROPEAN PARLIAMENT

of 24 April 2007

on closing the accounts of the European Medicines Agency for the financial year 2005

(2008/522/EC)

THE EUROPEAN PARLIAMENT,

— having regard to the final annual accounts of the European Medicines Agency for the financial year 2005 ([1]),

— having regard to the Court of Auditors' report on the final annual accounts of the European Medicines Agency for the financial year 2005, together with the Agency's replies ([2]),

— having regard to the Council's Recommendation of 27 February 2007 (5711/2007 — C6-0080/2007),

— having regard to the EC Treaty, and in particular Article 276 thereof,

— having regard to Council Regulation (EC, Euratom) No 1605/2002 of 25 June 2002 on the Financial Regulation applicable to the general budget of the European Communities ([3]), and in particular Article 185 thereof,

— having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency ([4]), and in particular Article 68 thereof,

— having regard to Commission Regulation (EC, Euratom) No 2343/2002 of 19 November 2002 on the framework Financial Regulation for the bodies referred to in Article 185 of Council Regulation (EC, Euratom) No 1605/2002 ([5]), and in particular Article 94 thereof,

— having regard to Rule 71 of and Annex V to its Rules of Procedure,

— having regard to the Report of the Committee on Budgetary Control and the opinion of the Committee on the Environment, Public Health and Food Safety (A6-0099/2007),

1. Notes that the final annual accounts of the European Medicines Agency for the financial years 2004 and 2005 are as follows:

Revenue and expenditure account for the financial years 2004 and 2005

(in EUR 1 000)

	2005	2004
Revenue		
Fees relating to marketing authorisations	72 613	68 412
Commission subsidy including contributions received from the EE	22 847	20 529
Community subsidy for orphan medicines	6 110	4 026

([1]) OJ C 266, 31.10.2006, p. 4.
([2]) OJ C 312, 19.12.2006, p. 12.
([3]) OJ L 248, 16.9.2002, p. 1. Regulation as amended by Regulation (EC, Euratom) No 1995/2006 (OJ L 390, 30.12.2006, p. 1).
([4]) OJ L 136, 30.4.2004, p. 1. Regulation as amended by Regulation (EC) No 1901/2006 (OJ L 378, 27.12.2006, p. 1).
([5]) OJ L 357, 31.12.2002, p. 72.

(in EUR 1 000)

	2005	2004
Contributions for Community programmes	0	0
Administrative revenue	3 423	1 973
Sundry revenue	1 643	1 473
Total revenue (a)	**106 636**	**96 413**
Expenditure		
Staff expenditure	40 057	34 333
Administrative expenditure	17 022	11 224
Operating expenditure	41 999	38 573
Depreciation	5 333	3 650
Other expenses	104	280
Total expenditure (b)	**104 515**	**88 060**
Operating result (c = a − b)	**2 121**	**8 353**
Financial result (e)	2 257	1 160
Economic outturn (f = c + e)	**4 378**	**9 513**

Source: The Agency's data — This table summarises the data provided by the Agency in its annual accounts;

2. Approves closing the accounts of the European Medicines Agency for the financial year 2005;

3. Instructs its President to forward this Decision to the executive director of the European Medicines Agency, the Council, the Commission and the Court of Auditors, and to arrange for its publication in the *Official Journal of the European Union* (L series).

The President — Hans-Gert PÖTTERING

The Secretary-General — Harald RØMER